AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11086179 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA chemotherapy (mitoxantrone, cytarabine, etoposide)
Number of subjects: 24
Study 8804872 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine glucose salt solution
Number of subjects: 19
Study 8804872 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine glucose salt solution
Number of subjects: 19
Study 8804872 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose alone
Number of subjects: 19
Study 1733435 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week chemohormonal regimen (cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, adriamycin, tamoxifen)
Number of subjects: 122
Study 1733435 — intervention group
Group type: COMPARATOR
Intervention: 36 weeks of CMFVP
Number of subjects: 122
Study 31454561 — intervention group
Group type: EXPERIMENTAL
Intervention: BENECA mHealth and rehabilitation for 2 months (n=40)
Number of subjects: 80
Study 31454561 — intervention group
Group type: COMPARATOR
Intervention: BENECA mHealth alone (n=40)
Number of subjects: 80
Study 31454561 — intervention group
Group type: EXPERIMENTAL
Intervention: BENECA mHealth and rehabilitation
Number of subjects: 80
Study 29886769 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity restriction for more than a week
Number of subjects: 1426
Study 29886769 — intervention group
Group type: COMPARATOR
Intervention: No activity restriction
Number of subjects: 1426
Study 28245352 — intervention group
Group type: EXPERIMENTAL
Intervention: Flortec (probiotic with prebiotic)
Number of subjects: 41
Study 28245352 — intervention group
Group type: COMPARATOR
Intervention: Control substance (starch)
Number of subjects: 41
Study 26346868 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site cytopathology evaluation (OCE+) during EUS-FNA
Number of subjects: 241
Study 26346868 — intervention group
Group type: COMPARATOR
Intervention: No on-site cytopathology evaluation (OCE-) during EUS-FNA
Number of subjects: 241
Study 24681963 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 80
Study 24681963 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast
Number of subjects: 80
Study 22859902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL)
Number of subjects: 120
Study 22859902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (0.5% lidocaine, 4 mL) mixed with 1 mL of nonparticulate betamethasone
Number of subjects: 120
Study 19363182 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention group (access to test results and learning activities)
Number of subjects: 905
Study 19363182 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention group (access to diagnostic tests results)
Number of subjects: 905
Study 19363182 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention group (access to learning activities)
Number of subjects: 905
Study 19363182 — intervention group
Group type: COMPARATOR
Intervention: Control group (business as usual)
Number of subjects: 905
Study 18404664 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week recall period
Number of subjects: 0
Study 18404664 — intervention group
Group type: COMPARATOR
Intervention: 1-day recall period
Number of subjects: 0
Study 16231263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation with dietary and exercise counseling
Number of subjects: 52
Study 16231263 — intervention group
Group type: COMPARATOR
Intervention: Dietary and exercise counseling alone
Number of subjects: 52
Study 12421058 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving objects depicted as transparent, opaque, or black cubes moving parallel to or intersecting the observer's path.
Number of subjects: 0
Study 12421058 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated observer movement over a ground plane.
Number of subjects: 0
Study 10349586 — intervention group
Group type: EXPERIMENTAL
Intervention: High school athletes
Number of subjects: 678
Study 10349586 — intervention group
Group type: COMPARATOR
Intervention: Nonathletes
Number of subjects: 678
Study 8953684 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin 1.5-2.0 g/day
Number of subjects: 515
Study 8953684 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime 3.0-4.5 g/day plus metronidazole 1.0-1.5 g/day
Number of subjects: 515
Study 8953684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 515
Study 2007851 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin/ibuprofen
Number of subjects: 25
Study 2007851 — intervention group
Group type: COMPARATOR
Intervention: Endotoxin alone
Number of subjects: 25
Study 2007851 — intervention group
Group type: COMPARATOR
Intervention: Endotoxin/pentoxifylline
Number of subjects: 25
Study 6211753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (100 micrograms)
Number of subjects: 8
Study 6211753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 8
Study 6211753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 8
Study 6211753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31488103 — intervention group
Group type: EXPERIMENTAL
Intervention: VR SCT (DiSCoVR)
Number of subjects: 100
Study 31488103 — intervention group
Group type: COMPARATOR
Intervention: VR relaxation training (VRelax; active control)
Number of subjects: 100
Study 27628742 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS)
Number of subjects: 199
Study 27628742 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Focused Treatment (PFT)
Number of subjects: 199
Study 27628742 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 199
Study 27628742 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAS and PFT
Number of subjects: 199
Study 27628742 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAS
Number of subjects: 199
Study 27628742 — intervention group
Group type: EXPERIMENTAL
Intervention: PFT
Number of subjects: 199
Study 26021246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg bid for 3 months
Number of subjects: 40
Study 26021246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ranolazine)
Number of subjects: 40
Study 24980066 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 25
Study 24980066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23129778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 index guided preoperative chemotherapy (paclitaxel and trastuzumab initially, modified based on Ki-67 index)
Number of subjects: 200
Study 23129778 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative chemotherapy (paclitaxel and trastuzumab)
Number of subjects: 200
Study 23129778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 index guided preoperative chemotherapy
Number of subjects: 200
Study 23129778 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative chemotherapy
Number of subjects: 200
Study 19387404 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Band (EB)
Number of subjects: 36
Study 19387404 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Chain (WC)
Number of subjects: 36
Study 19387404 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study 17352304 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for thrombophilia and receiving test results
Number of subjects: 1336
Study 17352304 — intervention group
Group type: COMPARATOR
Intervention: Testing for thrombophilia but not disclosing results
Number of subjects: 1336
Study 17352304 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional anticoagulant treatment for patients found to have thrombophilia
Number of subjects: 1336
Study 17352304 — intervention group
Group type: COMPARATOR
Intervention: Standard predefined duration of treatment for others
Number of subjects: 1336
Study 15531034 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 Immunotherapeutic (HPV16 E6E7 fusion protein and ISCOMATRIX adjuvant)
Number of subjects: 31
Study 15531034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15531034 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 Immunotherapeutic
Number of subjects: 31
Study 11417762 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine with indinavir added from week 12
Number of subjects: 47
Study 11417762 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine/lamivudine with indinavir added from week 12
Number of subjects: 47
Study 11417762 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine/lamivudine
Number of subjects: 47
Study 11417762 — intervention group
Group type: COMPARATOR
Intervention: Stavudine/lamivudine
Number of subjects: 47
Study 11417762 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF HIV-1 RNA levels
Number of subjects: 47
Study 11417762 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF indinavir concentration
Number of subjects: 47
Study 9792572 — intervention group
Group type: EXPERIMENTAL
Intervention: LT receptor antagonist (pranlukast, 450 mg/d)
Number of subjects: 6
Study 9792572 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA2 synthetase inhibitor (ozagrel, 800 mg/d)
Number of subjects: 6
Study 9792572 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA2 receptor antagonist (seratrodast, 80 mg/d)
Number of subjects: 6
Study 7825976 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan alone
Number of subjects: 20
Study 7825976 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan combined with total body irradiation
Number of subjects: 20
Study 7825976 — intervention group
Group type: EXPERIMENTAL
Intervention: busulphan plus melphalan
Number of subjects: 20
Study 7825976 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM association (BCNU + etoposide + high dose aracytine + high dose melphalan)
Number of subjects: 20
Study 7825976 — intervention group
Group type: EXPERIMENTAL
Intervention: all patients
Number of subjects: 20
Study 3241891 — intervention group
Group type: EXPERIMENTAL
Intervention: AO screws
Number of subjects: 110
Study 3241891 — intervention group
Group type: COMPARATOR
Intervention: Hook-pins
Number of subjects: 110
Study 31957558 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg DHA/day
Number of subjects: 167
Study 31957558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 29543499 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 37
Study 29543499 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Feedback (FB)
Number of subjects: 37
Study 29543499 — intervention group
Group type: COMPARATOR
Intervention: TAM device only (CTL)
Number of subjects: 37
Study 29543499 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM device
Number of subjects: 37
Study 28224397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen-specific food safety instruction
Number of subjects: 550
Study 28224397 — intervention group
Group type: COMPARATOR
Intervention: Basic food safety instruction (active control)
Number of subjects: 550
Study 26378978 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg or 25 mg once daily)
Number of subjects: 7020
Study 26378978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 26378978 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 24334183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO; 30 mg/d)
Number of subjects: 24
Study 24334183 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EXS; 90-120 min/d, 3 d/wk)
Number of subjects: 24
Study 24334183 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 20510464 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (10 Hz) rTMS over the left dorsolateral prefrontal cortex
Number of subjects: 14
Study 20510464 — intervention group
Group type: EXPERIMENTAL
Intervention: One session of rTMS
Number of subjects: 14
Study 18510207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention package (weekly 30-minute sessions for 7 weeks)
Number of subjects: 1275
Study 18510207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1275
Study 18510207 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (RMP training only)
Number of subjects: 1275
Study 16630304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro Cario L-Pop (CCLP) test
Number of subjects: 30
Study 16630304 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial toothpaste and mouthwash
Number of subjects: 30
Study 16630304 — intervention group
Group type: COMPARATOR
Intervention: Capillary ion electrophoresis (CIA) for lactic acid measurement
Number of subjects: 30
Study 12057884 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day)
Number of subjects: 491
Study 12057884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 10476937 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU of nHuIFN-alpha
Number of subjects: 368
Study 10476937 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of nHuIFN-alpha
Number of subjects: 368
Study 10476937 — intervention group
Group type: COMPARATOR
Intervention: 400 IU of nHuIFN-alpha
Number of subjects: 368
Study 10476937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 8726601 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions
Number of subjects: 12
Study 8726601 — intervention group
Group type: COMPARATOR
Intervention: Postprandial conditions
Number of subjects: 12
Study 1765528 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education package (PEP)
Number of subjects: 0
Study 1765528 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7076369 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of methadone
Number of subjects: 76
Study 7076369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of methadone
Number of subjects: 76
Study 7076369 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of methadone
Number of subjects: 76
Study 7076369 — intervention group
Group type: COMPARATOR
Intervention: Naloxone administration
Number of subjects: 76
Study 29672533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-type respirator with direct laryngoscope
Number of subjects: 26
Study 29672533 — intervention group
Group type: COMPARATOR
Intervention: GlideScope with cup-type respirator
Number of subjects: 26
Study 29672533 — intervention group
Group type: COMPARATOR
Intervention: i-gel with cup-type respirator
Number of subjects: 26
Study 29672533 — intervention group
Group type: COMPARATOR
Intervention: Fold-type respirator with any airway device
Number of subjects: 26
Study 27484821 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to generate a Continuity of Care Document (CCD) using the Blue Button feature of the VA patient portal
Number of subjects: 52
Study 27484821 — intervention group
Group type: COMPARATOR
Intervention: Attention control: Training to look up health information on the Internet
Number of subjects: 52
Study 27484821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing CCD prior to non-VA providers ordering laboratory tests
Number of subjects: 52
Study 27484821 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of medical records between VA and non-VA providers
Number of subjects: 52
Study 25664444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-RADS
Number of subjects: 26722
Study 25664444 — intervention group
Group type: COMPARATOR
Intervention: NLST
Number of subjects: 26722
Study 24136928 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM ER 7.5/46 mg
Number of subjects: 0
Study 24136928 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM ER 15/92 mg
Number of subjects: 0
Study 24136928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24136928 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 7.5 mg
Number of subjects: 0
Study 24136928 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 15 mg
Number of subjects: 0
Study 24136928 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate ER 46 mg
Number of subjects: 0
Study 24136928 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate ER 92 mg
Number of subjects: 0
Study 21094802 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept
Number of subjects: 27
Study 21094802 — intervention group
Group type: COMPARATOR
Intervention: cyclosporine
Number of subjects: 27
Study 18291550 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenems
Number of subjects: 1591
Study 18291550 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 1591
Study 18291550 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics
Number of subjects: 1591
Study 18291550 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with osteomyelitis
Number of subjects: 1591
Study 16845957 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper jaw extraction (two first or second premolars)
Number of subjects: 52
Study 16845957 — intervention group
Group type: COMPARATOR
Intervention: Upper and lower jaw extraction (four premolars)
Number of subjects: 52
Study 14669189 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific (TS) motor learning format
Number of subjects: 18
Study 14669189 — intervention group
Group type: COMPARATOR
Intervention: Task-nonspecific (TNS) motor learning format
Number of subjects: 18
Study 10607766 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) 10 ng/kg bodyweight/min
Number of subjects: 130
Study 10607766 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) 20 ng/kg bodyweight/min
Number of subjects: 130
Study 10607766 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) 40 ng/kg bodyweight/min
Number of subjects: 130
Study 10607766 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic sodium chloride solution)
Number of subjects: 130
Study 9193328 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2 and Cyclophosphamide 700 mg/m2 every 21 days
Number of subjects: 49
Study 9193328 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Cyclophosphamide 500 mg/m2 every 10 days
Number of subjects: 49
Study 9193328 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Cyclophosphamide 500 mg/m2 every 8 days
Number of subjects: 49
Study 8130662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohmeda Biox 3700 pulse oximeter
Number of subjects: 0
Study 8130662 — intervention group
Group type: COMPARATOR
Intervention: Baxter Asat 100 pulse oximeter
Number of subjects: 0
Study 3702764 — intervention group
Group type: EXPERIMENTAL
Intervention: Organon OD 14 (Tibolone)
Number of subjects: 15
Study 3702764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30664500 — intervention group
Group type: EXPERIMENTAL
Intervention: Active upper extremity neural mobilization
Number of subjects: 44
Study 30664500 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive upper extremity neural mobilization
Number of subjects: 44
Study 28278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Randomized Singular Value Thresholding (FRSVT)
Number of subjects: 0
Study 28278459 — intervention group
Group type: COMPARATOR
Intervention: Nuclear Norm Minimization (NNM)
Number of subjects: 0
Study 28278459 — intervention group
Group type: COMPARATOR
Intervention: Weighted Nuclear Norm Minimization (WNNM)
Number of subjects: 0
Study 27265742 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavituximab 3 mg/kg
Number of subjects: 121
Study 27265742 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Bavituximab 1 mg/kg
Number of subjects: 121
Study 25176263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 300
Study 25176263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cerebrolysin)
Number of subjects: 300
Study 22355055 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for high-grade gliomas
Number of subjects: 54
Study 19768515 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta ceramic-on-ceramic (COC)
Number of subjects: 263
Study 19768515 — intervention group
Group type: COMPARATOR
Intervention: Delta ceramic head-crosslinked polyethylene (COP)
Number of subjects: 263
Study 19142489 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg for 22 days
Number of subjects: 33
Study 19142489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15671123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine and phenylalanine deficient mixture (TP‐)
Number of subjects: 12
Study 15671123 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino-acid drink (Bal)
Number of subjects: 12
Study 14989050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 10785301 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 26
Study 10785301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 26
Study 10785301 — intervention group
Group type: EXPERIMENTAL
Intervention: Photac-Fil Quick
Number of subjects: 26
Study 10785301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpal pressure of 15cm H(2)O
Number of subjects: 26
Study 10785301 — intervention group
Group type: COMPARATOR
Intervention: No pulpal pressure
Number of subjects: 26
Study 8842609 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide gastrointestinal therapeutic system (GITS)
Number of subjects: 13
Study 8842609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1476025 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of allergen-antibody complexes made of D. pteronyssinus allergens and specific autologous antibodies.
Number of subjects: 23
Study 1476025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 23
Study 3157008 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg
Number of subjects: 40